Literature DB >> 16733250

Phosphorylation of amphiphysin I by minibrain kinase/dual-specificity tyrosine phosphorylation-regulated kinase, a kinase implicated in Down syndrome.

Noriko Murakami1, Wen Xie, Renne Chen Lu, Mo-Chou Chen-Hwang, Andrzej Wieraszko, Yu Wen Hwang.   

Abstract

Minibrain kinase/dual-specificity tyrosine phosphorylation-regulated kinase (Mnb/Dyrk1A) is a proline-directed serine/threonine kinase encoded in the Down syndrome critical region of human chromosome 21. This kinase has been shown to phosphorylate dynamin 1 and synaptojanin 1. Here we report that amphiphysin I (Amph I) is also a Mnb/Dyrk1A substrate. This kinase phosphorylated native Amph I in rodent brains and recombinant human Amph I expressed in Escherichia coli. Serine 293 (Ser-293) was identified as the major site, whereas serine 295 and threonine 310 were found as minor kinase sites. In cultured cells, recombinant Amph I was phosphorylated at Ser-293 by endogenous kinase(s). Because mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) has been suggested to phosphorylate Amph I at Ser-293, our efforts addressed whether Ser-293 is phosphorylated in vivo by MAPK/ERK or by Mnb/Dyrk1A. Overnight serum-withdrawal inactivated MAPK/ERK; nonetheless, Ser-293 was phosphorylated in Chinese hamster ovary and SY5Y cells. Epigallocatechin-3-gallate, a potent Mnb/Dyrk1A inhibitor in vitro, apparently reduced the phosphorylation at Ser-293, whereas PD98059, a potent MAPK/ERK inhibitor, did not. High frequency stimulation of mouse hippocampal slices reduced the phosphorylation at Ser-293, albeit in the midst of MAPK/ERK activation. The endophilin binding in vitro was inhibited by phosphorylating Amph I with Mnb/Dyrk1A. However, phosphorylation at Ser-293 did not appear to alter cellular distribution patterns of the protein. Our results suggest that Mnb/Dyrk1A, not MAPK/ERK, is responsible for in vivo phosphorylation of Amph I at Ser-293 and that phosphorylation changes the recruitment of endophilin at the endocytic sites.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16733250     DOI: 10.1074/jbc.M513497200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

2.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

3.  Spermiation: The process of sperm release.

Authors:  Liza O'Donnell; Peter K Nicholls; Moira K O'Bryan; Robert I McLachlan; Peter G Stanton
Journal:  Spermatogenesis       Date:  2011-01

4.  Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.

Authors:  Wieslaw K Dowjat; Tatyana Adayev; Izabela Kuchna; Krzysztof Nowicki; Sonia Palminiello; Yu Wen Hwang; Jerzy Wegiel
Journal:  Neurosci Lett       Date:  2006-12-04       Impact factor: 3.046

5.  MNB/DYRK1A phosphorylation regulates the interactions of synaptojanin 1 with endocytic accessory proteins.

Authors:  Tatyana Adayev; Mo-Chou Chen-Hwang; Noriko Murakami; Rong Wang; Yu-Wen Hwang
Journal:  Biochem Biophys Res Commun       Date:  2006-11-07       Impact factor: 3.575

6.  Intracellular distribution of differentially phosphorylated dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A).

Authors:  Wojciech Kaczmarski; Madhabi Barua; Bozena Mazur-Kolecka; Janusz Frackowiak; Wieslaw Dowjat; Pankaj Mehta; David Bolton; Yu-Wen Hwang; Ausma Rabe; Giorgio Albertini; Jerzy Wegiel
Journal:  J Neurosci Res       Date:  2013-11-22       Impact factor: 4.164

7.  Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A.

Authors:  Sergi Aranda; Mónica Alvarez; Silvia Turró; Ariadna Laguna; Susana de la Luna
Journal:  Mol Cell Biol       Date:  2008-08-04       Impact factor: 4.272

8.  Promotion of neuronal plasticity by (-)-epigallocatechin-3-gallate.

Authors:  Wen Xie; Narayan Ramakrishna; Andrzej Wieraszko; Yu-Wen Hwang
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

9.  Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.

Authors:  Fei Liu; Zhihou Liang; Jerzy Wegiel; Yu-Wen Hwang; Khalid Iqbal; Inge Grundke-Iqbal; Narayan Ramakrishna; Cheng-Xin Gong
Journal:  FASEB J       Date:  2008-05-28       Impact factor: 5.191

Review 10.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.